Publications

1. GVS advice metreleptin (Myalepta®)

   The National Health Care Institute advises the Minister to include metreleptin (Myalepta®) in List 1B of the GVS. Metreleptin is ...

   Report | 08-07-2022

2. GVS advice bempedoic acid (Nilemdo®) for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia

   The National Health Care Institute has completed its assessment whether bempedoic acid is interchangeable with another medicinal ...

   Report | 05-07-2022

3. GVS advice cannabidiol (Epidyolex®) as adjuvant treatment for 2 epileptic disorders

   The National Health Care Institute advises the Minister only to include cannabidiol (Epidyolex®) on List 1B of the Medicine ...

   Report | 04-07-2022

4. Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors

   The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...

   Report | 23-06-2022

5. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®): extension of further conditions

   The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

   Report | 20-06-2022

6. Implementation of the European health technology assessment legislation (EU HTAR)

   The National Health Care Institute is preparing for new European health technology assessment legislation which is going to be ...

   Publication | 01-06-2022

7. GVS advice bupropion in combination with naltrexone (Mysimba®)

   The National Health Care Institute advises the Minister to include bupropion in combination with naltrexone (Mysimba®) in the ...

   Report | 17-05-2022

8. GVS advice GLP-1 receptor agonists extension further conditions

   The National Health Care Institute advises the Minister to extend the reimbursement conditions for dulaglutide, exenatide, ...

   Report | 16-05-2022

9. GVS advice to not include pitolisant (Ozawade®)

   The National Health Care Institute has completed its assessment whether pitolisant (Ozawade®) can be included in the Medicine ...

   Report | 10-05-2022

10. Package advice on zanubrutinib (Brukinsa®) for the treatment of Waldenström macroglobulinaemia (WM)

    The National Health Care Institute advises the Minister to include zanubrutinib (Brukinsa®) in the basic health insurance package ...

    Report | 27-04-2022